Abstract
Neurofibromatosis type 1 (NF1) and its related disorders (NF1-Noonan syndrome (NFNS) and Watson syndrome (WS)) are caused by heterozygous mutations in the NF1 gene. Pulmonary stenosis (PS) occurs more commonly in NF1 and its related disorders than in the general population. This study investigated whether PS is associated with specific types of NF1 gene mutations in NF1, NFNS and WS. The frequency of different NF1 mutation types in a cohort of published and unpublished cases with NF1/NFNS/WS and PS was examined. Compared with NF1 in general, NFNS patients had higher rates of PS (9/35=26% vs 25/2322=1.1%, P value<0.001). Stratification according to mutation type showed that the increased PS rate appears to be driven by the NFNS group with non-truncating mutations. Eight of twelve (66.7%) NFNS cases with non-truncating mutations had PS compared with a 1.1% PS frequency in NF1 in general (P<0.001); there was no increase in the frequency of PS in NFNS patients with truncating mutations. Eight out of eleven (73%) individuals with NF1 and PS, were found to have non-truncating mutations, a much higher frequency than the 19% reported in NF1 cohorts (P<0.015). Only three cases of WS have been published with intragenic mutations, two of three had non-truncating mutations. Therefore, PS in NF1 and its related disorders is clearly associated with non-truncating mutations in the NF1 gene providing a new genotype–phenotype correlation. The data indicate a specific role of non-truncating mutations on the NF1 cardiac phenotype.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Evans DG, Howard E, Giblin C et al: Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010; 152A: 327–332.
Ferner RE : Neurofibromatosis 1; in Ferner RE, Huson SM, Evans DGR (eds): Neurofibromatoses in Clinical Practice. London: Springer, 2011, pp 1–46.
Messiaen LM, Callens T, Mortier G et al: Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000; 15: 541–555.
Messiaen LM, Wimmer K : NF1 mutation spectrum; in Kaufmann D, (ed.): Neurofibromatoses. Basel: Karger, 2008, pp 63–77.
Kluwe L, Siebert R, Gesk S et al: Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 2004; 23: 111–116.
Le LQ, Parada LF : Tumour microenvironement and neurofibromatosis type 1: connecting the GAPs. Oncogene 2007; 26: 4609–4616.
Jouhilahti EM, Peltonen S, Heam AM, Peltonen J : Pathoaetiology of neurofibromatosis type one. Am J Pathol 2011; 178: 1392–1399.
Mautner VF, Kluwe L, Friedrich RE et al: Clinical characterisation of 29 neurofibromatosis type one patients with molecularly aseratined 1.4 Mb type one NF1deletions. J Med Genet 2010; 47: 623–630.
Upadhyaya M, Huson SM, Davies M et al: An absence of cutaneous neurofibromas associated with a 3-bp in-frame deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 2007; 80: 140–151.
Brems H, Chmara M, Sahbatou M et al: Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007; 39: 1120–1126.
Denayer E, Chmara M, Brems H et al: Legius syndrome in fourteen families. Hum Mutat 2011; 32: E1985–E1998.
Phoenix TN, Temple S : Spred1, a negative regulator of Ras-MAPK-ERK, is enriched in CNS germinal zones, dampens NSC proliferation, and maintains ventricular zone structure. Genes Dev 2010; 24: 45–56.
Watson GH : Pulmonary stenosis, café -au-lait spots, and dull intelligence. Arch Dis Child 1967; 42: 303–307.
Allanson JE, Upadhyaya M, Watson GH et al: Watson syndrome: is it a sub-type of neurofibromatosis? J Med Genet 1991; 28: 752–756.
Tassabehji M, Strachan T, Sharland M et al: Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a family with features of Watson syndrome and Noonan syndrome. Am J Hum Genet 1993; 53: 90–95.
Upadhyaya M, Shen M, Cherryson A et al: Analysis of mutations at the neurofibromatosis 1 (NF1) locus. Hum Mol Genet 1992; 1: 735–740.
Colley A, Donnai D, Evans DG : Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clin Genet 1996; 49: 59–64.
De Luca A, Bottillo I, Sarkozy A et al: NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet 2005; 77: 1092–1101.
Nyström AM, Ekvall S, Allanson J et al: Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1. Clin Genet 2009; 76: 524–534.
Bertola DR, Pereira AC, Passetti F et al: Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. Am J Med Genet A 2005; 136: 242–245.
Thiel C, Wilken M, Zenker M et al: Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-noonan syndrome. Am J Med Genet A 2011; 149A: 1263–1267.
Rauen KA, Banerjee A, Bishop WR et al: Costello and cardio-facio-cutaneous syndromes: moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet 2011; 157: 136–146.
Lin AE, Birch PH, Korf BR et al: Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am J Med Genet 2000; 95: 108–117.
Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R : Functional annotations improve the predictive score of human disease-related mutations in proteins. Hum Mutat 2009; 30: 1237–1244.
Hüffmeier U, Zenker M, Hoyer J, Fahsold R, Rauch A : A variable combination of features of Noonan syndrome and neurofibromatosis type I are caused by mutations in the NF1 gene. Am J Med Genet A 2006; 140: 2749–2756.
Baralle D, Mattocks C, Kalidas K et al: Different mutations in the NF1 gene are associated with neurofibromatosis-Noonan syndrome (NFNS). Am J Med Genet A 2003; 119A: 1–8.
Stevenson DA, Viskochil DH, Rope AF, Carey JC : Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype. Clin Genet 2006; 69: 246–253.
Castle B, Baser ME, Huson SM, Cooper DN, Upadhyaya M : Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet 2003; 40: e109.
Sharif S, Upadhyaya M, Ferner R et al: A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet 2011; 48: 256–260.
Messiaen L, Callens T, Williams JB et al: Genotype-phenotype correlations in spinal NF. (Abstract 985) Presented at the annual meeting of The American Society of Human Genetics, 25 October 2007, San Diego, California. Available from: http://www.ashg.org/genetics/ashg07s/index.shtml.
Upadhyaya M, Spurlock G, Kluwe L et al: The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas. Neurogenetics 2009; 10: 251–263.
Thomas L, Richards M, Mort M, Dunlop E, Cooper DN, Upadhyaya M : Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene. Hum Mut 2012; e-pub ahead of print 16 July 2012; doi: 10.1002/humu.22162.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ben-Shachar, S., Constantini, S., Hallevi, H. et al. Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype–phenotype correlation. Eur J Hum Genet 21, 535–539 (2013). https://doi.org/10.1038/ejhg.2012.221
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2012.221
Keywords
This article is cited by
-
Neurofibromatosis-Noonan syndrome and growth deficiency in an Iranian girl due to a pathogenic variant in NF1 gene
Human Genomics (2023)
-
Natural history of NF1 c.2970_2972del p.(Met992del): confirmation of a low risk of complications in a longitudinal study
European Journal of Human Genetics (2022)
